Bioanalysis explores novel LC-MS assays impacting CYP and transporter DDI evaluations

May 30, 2018

Bioanalysis, a leading MEDLINE indexed journal for bioanalytical scientists, has published a Special Focus Issue on LC-MS assays impacting CYP and transporter DDI evaluations. The journal is published by Future Science Group.

The Special Focus Issue, guest Edited by Ragu Ramanathan (Pfizer), explores novel LC-MS assays impacting CYP and transporter DDI evaluations, through original research articles, as well as expert perspectives in the form of commentary-style articles.

The issue discusses new technologies in MS as well as looking into multiplexing, and getting more information using HRMS, as well as sample pooling approaches. Proposals of several endogenous biomarkers for evaluating DDI at early stages in clinical trials, so DDI studies do not need to be continued into the latter stages, are also explored.

"There is a growing interest in exploring novel LC-MS/MS, LC-high resolution accurate MS (LC-HRMS), or LC-MS/HRMS assays early in drug development to ensure DDI related liabilities to establish safety and efficacy of a NCE. This special issue brings together some the novel LC-MS applications and outlook from leaders in the field" said Ragu Ramanathan (Pfizer).

"I am delighted to have worked with experts in the field to produce this Special Focus Issue, which appears to demonstrate the expansion of interest in using sensitive and selective LC-MS assays for evaluations of DDI potentials early in development of new chemical entities to assure safety and efficacy." commented Sankeetha Nadarajah (Managing Commissioning Editor, Bioanalysis).

To read the full issue, please visit

The guest editors' free-access foreword article is available online here:
About Bioanalysis

Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.

About Bioanalysis Zone

Since launching in 2011, Bioanalysis Zone has attracted over 7,500 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries. Membership is completely free of charge. Sign up online at:

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

Future Science Group

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to